To evaluate the effect of AZD3199 on the electrical activity in the heart

Study identifier:D0570C00004

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A single-centre, randomised, double-blind, double-dummy, placebo controlled, 4-way crossover Phase I study to investigate the effect of 2 single doses (400 μg and 1200 µg) of inhaled AZD3199 on QT/QTc interval, compared to placebo, using moxifloxacin (Avelox®) as a positive control, in healthy male volunteers

Medical condition

Chronic Obstructive Pulmonary Disease

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD3199, Moxifloxacin

Sex

Male

Actual Enrollment

40

Study type

Interventional

Age

18 Years - 45 Years

Date

Study Start Date: 01 Nov 2010
Primary Completion Date: 01 Feb 2011
Study Completion Date: 01 Feb 2011

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria